ChemicalBook > CAS DataBase List > Inebilizumab

Inebilizumab

Product Name
Inebilizumab
CAS No.
1299440-37-1
Chemical Name
Inebilizumab
Synonyms
Inebilizumab;Inebilizumab (anti-CD19);Research Grade Inebilizumab;Research Grade Inebilizumab(DHD10802);MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551
CBNumber
CB18080940
Formula Weight
0
MOL File
Mol file
More
Less

Inebilizumab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Inebilizumab Chemical Properties,Usage,Production

Uses

Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].

in vivo

Inebilizumab (MEDI-551) (0-10 mg/kg; i.v.; once) depletes B cells from blood and spleen by mouse macrophages in vivo and phagocytosis of murine B cells ex vivo[2].

Animal Model:huCD19/CD20 double Tg mice[2]
Dosage:0.5, 2, or 10 mg/kg
Administration:Tail vein injection, once
Result:Depleted B cells from blood and spleen, B-cell depletion in blood and spleen was maintained for more than 2 weeks after a single 10 mg/kg administration (better than Rituximab). Resulted in a substantial reduction (on average by 91.4% by day 3) in BM B220+muCD19+ B cells. Led to depletion of B cell by mouse macrophages.

References

[1] Chen D, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med. 2016 Nov 24;5(12):107. DOI:10.3390/jcm5120107
[2] Herbst R, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010 Oct;335(1):213-22. DOI:10.1124/jpet.110.168062

Inebilizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Inebilizumab Suppliers

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58

1299440-37-1, InebilizumabRelated Search:


  • Inebilizumab
  • Research Grade Inebilizumab(DHD10802)
  • Inebilizumab (anti-CD19)
  • MEDI 551|||MT-0551|||16C4-aFuc|||VIB-0551
  • Research Grade Inebilizumab
  • 1299440-37-1